ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 7.84M |
| Revenue (ttm) | 10.85M |
| Net Income (ttm) | -45.17M |
| Shares Out | 3.53M |
| EPS (ttm) | -17.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,600 |
| Average Volume | 63,901 |
| Open | 2.040 |
| Previous Close | 2.040 |
| Day's Range | 2.040 - 2.270 |
| 52-Week Range | 2.000 - 34.200 |
| Beta | 2.59 |
| RSI | 25.13 |
| Earnings Date | May 5, 2026 |
About STO:EXPRS2
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma... [Read more]
Financial Performance
In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.04 million, -60.57% less than in 2023.
Financial StatementsNews
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q4 2025
Q4 and full year 2025 saw strong clinical and financial progress, with income up 56% year-on-year and a significantly improved underlying net loss. The pipeline advanced in oncology and infectious diseases, supported by grant funding and a solid cash position for 2026 milestones.
ExpreS2ion Biotech Holding AB Transcript: Life Science Summit 2025
A novel HER2-targeted therapeutic vaccine is advancing through phase I trials, showing promising immune responses and potential to address high unmet needs in breast cancer. The therapy targets a large, growing market and is supported by a strong pipeline, recent partnerships, and a solid financial position.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q3 2025
Q3 saw strong execution with increased income, improved net loss, and expanded global partnerships, including a major malaria vaccine license. Cash runway extends into Q2 2026, with key clinical and partnership milestones expected over the next 18 months.
ExpreS2ion Biotech Holding AB Transcript: Investing in Life Science 2025
A novel immunotherapy targeting all HER2 domains in breast cancer shows strong preclinical and early clinical results, with phase I data progressing and broader market expansion planned. Strategic partnerships and prudent financial management support a EUR 5 billion+ addressable market.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q2 2025
Strong pipeline progress with the breast cancer vaccine trial expanding and new partnerships in malaria and influenza. H1 2025 income rose 61% year-over-year, with a SEK 49 million cash position providing runway through Q1 2026. Key data readouts expected in 2026.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q1 2025
Q1 saw a 90% rise in operating income and 44% growth in net sales, with a reduced net loss and strong cash position. ESGBC001 phase I trial is advancing with protocol amendments, while infectious disease programs progress through grant funding and partnerships.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q4 2024
Q4 2024 saw a 5% drop in operating income and a SEK 16 million net loss, but year-end cash rose to SEK 82 million. Key milestones included CTA approval for the breast cancer vaccine, a major warrant subscription, and ongoing negotiations with the Serum Institute for malaria vaccines.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q3 2024
Q3 saw a narrowed net loss and reduced costs, with SEK 76 million in cash and a successful rights issue. Key milestones include a pending phase 1 trial for the breast cancer vaccine, a term sheet with Serum Institute of India, and progress in grant-funded projects.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q2 2024
H1 2024 saw improved financials with a net profit in Q2, boosted by a SEK 22.5 million dividend and a SEK 30 million rights issue. The lead breast cancer vaccine candidate is on track for a phase I trial in Q1 2025, with funding dependent on warrant exercises.